Corona Remedies IPO opens today; should you subscribe?
Corona Remedies's IPO is now open for subscription until December 10, offering 61.71 lakh shares at ₹1,008-1,062 each.
The company aims to raise about ₹655 crore through this offer for sale by existing shareholders.
What does the company do?
Started in 2004, Corona Remedies is an Indian pharma company known for branded medicines in women's health, cardio-diabetes care, pain management, and urology.
It's grown fast—ranking second among India's top 30 pharma firms by domestic sales from June 2022 to June 2025.
Other key details
Most of its revenue comes from the Indian market. With two EU and WHO-certified plants and a new hormone facility in progress (ready by FY27), it's focused on growth.
The IPO is priced similarly to peers; analysts like SBI Securities and Anand Rathi recommend it for long-term investors thanks to its solid balance sheet and expansion plans.